|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174.90 CHF | -0.06% |
|
+5.70% | +8.64% |
| Jul. 21 | Celldex to stop skin disease study after trial setback | RE |
| Jul. 09 | RBC Expects Slowdown in Galderma's Q2 Sales Growth; Price Target, Estimates Revised | MT |
Search
No results match your criteria
- Stock Market
- Stocks
- GALD Stock
- News Galderma Group AG
Select your edition
All financial news and data tailored to specific country editions
















